Biomedical medical device commercialization entrepreneurial training, see attached statement of work for details.
Ended Purchase Order Awarded Last action
- Contract number
- 75N92019P00328
- Awardee
-
Biocomx UEI FHLJUBQ8YAL7
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $14,364,855
Award facts
- Opportunity
-
- 75N92019R0055 Solicitation number
- Biomedical medical device commercialization entrepreneurial training supplement Award Notice · Posted May 15, 2020
- Biomedical medical device commercialization entrep Award Notice · Posted Jul 25, 2019
- Contract value 96% obligated
-
- $14,364,855.00 Current, with exercised options
- $14,949,405.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 611430 Professional and Management Development Training
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 3 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- MONARCH BAY, CA 92629, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
- National interest action
- Coronavirus COVID-19
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $3,000,000 | |
| Funding Only Action | $3,075,140 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $595,600 | |
| Exercise an Option | $3,076,500 | |
| Funding Only Action | $4,059,925 | |
| Original award | $557,690 |
About this award
The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded a $14,949,405.00 firm-fixed-price purchase order to Biocomx, a minority-owned, Hispanic American-owned non-profit organization. The contract is for the Biomedical Medical Device Commercialization Entrepreneurial Training program, which aligns with the National Interest Action Code for the Coronavirus COVID-19 pandemic. Biocomx provides training and support to early-stage biomedical project teams to help them commercialize innovations. This includes delivering the BiocomxC3i Program, a training curriculum based on the Coulter Commercialization Process, to assist entrepreneurs and small businesses in starting new companies and moving technologies toward commercialization and clinical use. Biocomx has previously received federal contract awards from the NIH and Department of Veterans Affairs for similar biomedical entrepreneurship and commercialization programs. The contract does not have a set-aside designation.
Quick answers
Who was awarded contract 75N92019P00328?
75N92019P00328 was awarded to Biocomx by National Heart Lung and Blood Institute (National Institutes of Health) on August 16, 2019.
How much is contract 75N92019P00328 worth?
The government has obligated $14,364,855 on 75N92019P00328. Its potential value, with all options, is $14,949,405.
Was contract 75N92019P00328 competed?
The extent of competition for 75N92019P00328 was competed under sap. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award